EKF Diagnostics (LON:EKF) Stock Passes Above 200-Day Moving Average of $28.41

EKF Diagnostics Holdings plc (LON:EKF) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 28.41 ($0.35) and traded as high as GBX 28.72 ($0.35). EKF Diagnostics shares last traded at GBX 27.80 ($0.34), with a volume of 183,640 shares changing hands.

EKF Diagnostics Stock Down 0.7 %

The firm’s fifty day moving average price is GBX 27.33 and its two-hundred day moving average price is GBX 28.41. The stock has a market cap of £125.23 million, a price-to-earnings ratio of 2,760.00 and a beta of 0.58. The company has a debt-to-equity ratio of 6.01, a current ratio of 2.69 and a quick ratio of 1.77.

Insider Transactions at EKF Diagnostics

In other EKF Diagnostics news, insider Christopher H. B. Mills bought 100,000 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was bought at an average cost of GBX 26 ($0.32) per share, with a total value of £26,000 ($32,114.62). 5.11% of the stock is currently owned by insiders.

About EKF Diagnostics

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples.